1. Scrip
  2. >>Digital Technologies

How To Speed Up MLR Reviews: A Master Class By J&J, UCB, ex-Takeda Heads

 
• By Vibha Ravi

A panel of experts from J&J, UCB and Takeda deliberated on the use of AI and internal processes to strike the right balance between speed and accuracy in MLR reviews that could protect a company from serious repercussions

Speakers from J&J, UCB And Takeda On The MLR Review Panel At Indegene Digital Summit 2024
Speakers On The MLR Review Panel At Indegene Digital Summit 2024 (Indegene)

Be quick or be safe? That’s a dilemma the pharmaceutical industry faces often as it seeks to bring a new drug to any market.

A panel of medical, legal, regulatory (MLR) review experts, including an ex-Takeda head and present heads of Johnson & Johson...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

Lilly Provides AI/ML Modeling To Smaller Firms Via New Platform

 
• By Alaric DeArment

The drugmaker launched TuneLab, part of Catalyze360, which gives partners access to its artificial intelligence/machine learning drug discovery model trained on its research data.

E-Pharmacies In India: Mind The Data Privacy Gap, Regulatory Deficit

 
• By Anju Ghangurde

Legal and other experts discuss the need to plug data privacy and regulatory gaps and address prescription shortcuts at e-pharmacies. Collaborative models with brick-and-mortar chemists were also proposed.

Opportunities For AI In Pricing, Reimbursement Abound, But Use Remains Rare

 
• By Alaric DeArment

A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.

More from Business

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Asia Deal Watch: Aditum Founds Kalexo With Mabwell To Develop Dual-Target SiRNA Asset

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, Vibha Ravi, and Lisa Takagi

Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.